CLDX — Celldex Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 744218 ·
Last close
$28.04
Market Cap
$2.20B
52W High
$45.14
52W Low
$22.33
ADV30
1,089,357
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -82,251,000 | -75,557,000 | 721,531,000 | 26,952,000 | 72,062,000 |
| Jun 2026 | 22,000 | — | -80,623,000 | -73,503,000 | 782,349,000 | 47,454,000 | 67,785,000 |
| Mar 2026 | 15,000 | — | -84,435,000 | -78,685,000 | 511,254,000 | 35,729,000 | 55,028,000 |
| Dec 2025 | 121,000 | — | -87,153,000 | -81,317,000 | 582,983,000 | 28,871,000 | 55,818,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-235,566,000
Investing CF
$-67,131,000
Financing CF
$327,107,000
CapEx
$-6,539,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.35
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,966,169,000
Inventory
—
Receivables
$230,000
ST Investments
$670,133,000
EBIT TTM
$-325,828,000
Pretax Income TTM
$-300,549,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$158,000
EBITDA
$-330,728,000
Free Cash Flow
$-154,987,744
Enterprise Value
$1,705,691,648
Total Cash
$650,318,976
Total Debt
$9,870,000
Shares Out
78,545,051
Trailing EPS
$-4.29
Book Value
$8.27
ROE
-49.5%
ROA
-30.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,545,000 | -287,367,000 | -258,757,000 | 582,983,000 | 55,818,000 | 527,165,000 | -210,945,000 |
| Dec 2024 | 7,020,000 | -195,078,000 | -157,863,000 | 792,340,000 | 45,335,000 | 747,005,000 | -157,778,000 |
| Dec 2023 | 6,883,000 | -142,042,000 | -141,429,000 | 465,627,000 | 36,456,000 | 429,171,000 | -107,291,000 |
| Dec 2022 | 2,357,000 | -107,096,000 | -112,325,000 | 352,735,000 | 26,531,000 | 326,204,000 | -103,732,000 |
TTM Snapshot
Revenues TTM
$157,000
NetIncome TTM
$-300,549,000
OpCashFlow TTM
—
Assets (Latest)
$782,349,000
Forward EPS
$-4.21
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NEOG | NEOGEN CORP | $2.38B | $10.90 | — |
| NTLA | Intellia Therapeutics, Inc. | $1.37B | $9.78 | — |
| ABSI | Absci Corp | $1.31B | $7.58 | — |
| OABI | OmniAb, Inc. | $736.59M | $5.05 | — |
| LNTH | Lantheus Holdings, Inc. | $6.66B | $101.80 | — |
News headlines (Yahoo Finance, 1h cache)
Guggenheim reiterates this biotech stock as a top pick
2026-11-10 14:10 · Yahoo
Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results
2026-11-10 06:12 · Yahoo
Celldex Stock In Focus After Earnings Loss And Shelf Filing
2026-11-06 20:14 · Yahoo
Celldex: Q3 Earnings Snapshot
2026-11-05 21:26 · Yahoo
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
2026-11-05 21:01 · Yahoo
Celldex to Present at Upcoming Investor Conferences
2026-11-04 21:01 · Yahoo
Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation
2026-10-17 00:15 · Yahoo
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
2026-09-23 12:41 · Yahoo
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
2026-09-22 17:10 · Yahoo
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
2026-09-22 16:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.